Cannabidiol
 |
|
 |
|
| Clinical data | |
|---|---|
| Trade names | Epidiolex |
| AHFS/Drugs.com | International Drug Names |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 13–19% (oral), 11–45% (mean 31%; inhaled) |
| Biological half-life | 9 h |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ECHA InfoCard | 100.215.986 |
| Chemical and physical data | |
| Formula | C21H30O2 |
| Molar mass | 314.4636 |
| 3D model (Jmol) | |
| Melting point | 66 °C (151 °F) |
| Boiling point | 180 °C (356 °F) (range: 160–180 °C) |
|
|
|
|
  (what is this?)
|
|
Cannabidiol (INN) (CBD) is one of at least 113 active cannabinoids identified in cannabis. It is a major , accounting for up to 40% of the plant's extract. CBD is considered to have a wide scope of potential medical applications – due to clinical reports showing the lack of side effects, particularly a lack of psychoactivity (as is typically associated with ∆9-THC), and non-interference with several psychomotor learning and psychological functions.
Dravet syndrome is a rare form of epilepsy that is difficult to treat. It is a catastrophic form of intractable epilepsy that begins in infancy. Initial seizures are most often prolonged events and in the second year of life other seizure types begin to emerge. A number of high profile and anecdotal reports have sparked interest in treatment of Dravet syndrome with cannabidiol.
Some cannabis/hemp extract preparations containing CBD are marketed as dietary supplements and claim efficacy against Dravet syndrome. One such preparation is marketed under the tradename Charlotte's Web Hemp Extract.
GW Pharmaceuticals is seeking FDA approval to market a liquid formulation of pure plant-derived CBD, under the trade name Epidiolex (containing 99% cannabidiol and less than 0.10% Δ9-THC) as a treatment for Dravet syndrome. Epidiolex was granted fast-track status and is in late stage trials following positive early results from the drug.
A 2014 review stated that cannabidiol has been claimed, anecdotally, to be of benefit in helping people with epilepsy. Information in the review stated that there is no established mechanism of action and the lack of high-quality evidence in this area precluded conclusions being drawn.
A 2016 review states that because of the poor quality of available data, "no conclusions can be drawn" about the effectiveness of cannabidiol as an epilepsy treatment.
...
Wikipedia